{"contentid": 488198, "importid": NaN, "name": "New treatment for rare bile duct cancer in Europe", "introduction": "Incyte has won European approval for Pemazyre (pemigatinib), as a second-line option for certain people with locally advanced or metastatic bile duct cancer.", "content": "<p>Incyte (Nasdaq: INCY) has won European approval for Pemazyre (pemigatinib), as a second-line option for certain people with locally-advanced or metastatic bile duct cancer.</p>\n<p>Also known as cholangiocarcinoma, the rare type of cancer is often diagnosed at a late or advanced stage when the prognosis is poor.</p>\n<p>It affects between 6,000 and 8,000 people in Europe.</p>\n<p>The decision was widely anticipated, after a positive opinion from the European Medicines Agency&rsquo;s scientific body in January 2021.</p>\n<p>The firm has secured conditional marketing authorization (CMA), and may be required to provide confirmatory data in the future.</p>\n<h2>Breakthrough option</h2>\n<p>The decision from the European regulator comes around a year after the US Food and Drug Administration gave the green light under the similar Accelerated Approval scheme, making it the first and only FDA-approved treatment for this indication.</p>\n<p>At the same time, the US FDA approved FoundationOne CDx, a companion diagnostic for Pemazyre which is designed to help identify people with FGFR2 fusions or rearrangements who may be eligible for treatment with Pemazyre.</p>\n<p>There are other FGFR blockers under development in oncology, including Balversa (erdafitinib), from Johnson &amp; Johnson (NYSE: JNJ), which has been approved in the USA for bladder cancer.</p>\n<p>Commenting on the regulatory decision, chief executive Herv&eacute; Hoppenot said: &ldquo;Pemazyre&rsquo;s approval is a crucial milestone for patients with FGFR2 positive cholangiocarcinoma.&rdquo;</p>\n<p>He added: &ldquo;It is the first new treatment option to be made available to these patients in the EU in over a decade and has demonstrated a high rate of durable responses in a setting where historically there has been no effective standard of care.&rdquo;</p>", "date": "2021-03-30 12:15:00", "meta_title": NaN, "meta_keywords": "cancer, bile, duct, European, people, option, Pemazyre, treatment, approval, advanced, Europe, rare, pemigatinib, second-line, Incyte, locally, metastatic", "meta_description": "Incyte has won European approval for Pemazyre (pemigatinib), as a second-line option for certain people with locally advanced or metastatic bile duct cancer.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 11:45:58", "updated": "2021-03-30 12:15:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/new-treatment-for-rare-bile-duct-cancer-in-europe", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "incytebig.jpg", "image2id": "incytesmall.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "USA", "company_tag": "Incyte", "drug_tag": "Pemazyre", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 12:15:00"}